| Summary: | Background: bladder cancer is one of the most common urinary tract malignancies. Establishment of robust predictors of disease progression and outcome is important for personalizing treatment of non-muscular invasive bladder carcinoma (NMIBC). In this study we evaluated association of PD-L1 expression with other prognostic biomarkers, such as expression of miRNA-145 and miRNA-200a, <i>FGFR3</i> gene expression, and mutation status in tissue specimens of the luminal subtype of newly diagnosed high and low grade NMIBC. Methods: twenty patients with primary luminal NMIBC were enrolled in the study. Tumor grade and risk level were determined in accordance with European Organization for Research and Treatment of Cancer (EORTC) guidelines and World Health Organization (WHO) classification. Neoplasm molecular subtype and PD-L1 expression level were assessed by immunohistochemistry. We used real-time PCR to evaluate the expression of microRNAs and <i>FGFR3</i>. We detected <i>FGFR3</i> hotspot mutations in codons 248 and 249 by Sanger sequencing. Results: high grade primary luminal NMIBC showed comparatively higher expression of PD-L1 and microRNA-145 than a low grade tumor, whereas the latter had a higher <i>FGFR3</i> expression and hotspot mutation rate. The tumor grade (HR = 571.72 [11.03–2.96] <i>p</i> = 0.002), PD-L1 expression (HR = 2.33 [0.92–1.92] <i>p</i> = 0.012), and <i>FGFR3</i> expression (HR = 0.08 [0.17–0.42] <i>p</i> = 0.003) were associated with relapse-free survival. Conclusions: tumor grade in association with PD-L1 and <i>FGFR3</i> expression can be considered as a complex predictor for primary luminal NMIBC progression.
|
|---|